通过计算和基于细胞的研究,阐明他类药物对瘤性c-Met Tyrosine Kinase的抑制潜力
Elham Ahmad Alizadeh1, Leila Karami2, Fahimeh Ghasemi3
1Department of Pharmacy, Eastern Mediterranean University, Famagusta, North Cyprus.
Iranian journal of pharmaceutical research : IJPR
|October 17, 2025
概括
这项研究研究了他类药物作为胃癌中c-Met途径的潜在抑制剂. 虽然弗鲁瓦斯塔丁和皮塔瓦斯塔丁表现出细胞毒性,但它们没有显著影响c-Met信号传递.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- c-Met受体氨酸激酶是各种癌症的治疗点,包括胃癌.
- 过度表达c-Met和肝细胞生长因子 (HGF) 与预后不佳有关.
- 众所周知可以降低LDL的他类药物,通过类作用具有抗癌性质.
研究的目的:
- 通过计算和实验方法确定抑制c-Met信号的最有效的他类药物.
- 评估他类药物对胃癌细胞的抗癌潜力.
- 探索他类药物对c-Met通路的作用机制.
主要方法:
- 开发了机器学习模型来预测对c-Met的他类药物活性.
- 分子对接和分子动力学模拟评估了生物分子相互作用.
- 在胃癌细胞系 (AGS和MKN-45) 上进行了细胞毒性,流细胞计和西部斑检测.
主要成果:
- 机器学习预测了针对拟议的他类药物结构的高抑制活性 (> 200 nM).
- 弗卢瓦斯塔丁和皮塔瓦斯塔丁在中显示出最高的抑制潜力.
- 在基于细胞的测试中,这些他类药物在胃癌细胞中诱导了细胞毒性和亡,并积累了亚G1 DNA 内容.
- 西部斑点分析显示,c-Met酸化没有显著减少.
结论:
- 类药物,包括素和皮塔素,对胃癌细胞表现出细胞毒性和亡性作用.
- 没有观察到这些他类药物对c-Met通路酸化的直接抑制作用.
- 这项研究没有确定他类药物诱导的抑制与癌细胞中c-Met途径之间的联系.
相关概念视频
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K